Indivumed Announces New Product: Automated Immunohistochemistry Services For The Drug Discovery And Development Market
Washington, DC - Indivumed announces the launch of immunohistochemistry (IHC) and in situ hybridization (ISH) laboratory services for the cancer drug discovery and development market. Today, Hartmut Juhl, M.D., Ph.D., Indivumed's CEO, described Indivumed's new IHC and ISH capabilities at a molecular histopathology seminar in London, UK, sponsored in part by Ventana Medical Systems. Ventana, whose technology Indivumed employs, is a market leader in automated systems for IHC and ISH analyses that measure important proteins to target against cancer.
The advantage to the market of Indivumed's IHC services will be the tumor biobank of cancer tissue, to which customers will have access, which Indivumed routinely collects across all cancer types. The standard by which these tissues and corresponding clinical data are collected exceeds the U.S. National Cancer Institute's recently published (June 2007) Best Practices for Biospecimen Resources for tissue and data quality. Access to these high quality tissues at routine IHC costs will produce results that reflect the molecular reality of cancer, thereby benefiting pharmaceutical and biopharmaceutical companies developing cancer drugs.
Indivumed is a privately held biotech company focused on the generation, characterization and interpretation of highly standardized biological samples from human cancer. Founded in 2002 and headquartered in Hamburg, Germany with a subsidiary in Washington DC, Indivumed has cooperation agreements with all major oncological hospitals in the Hamburg metropolitan area. Indivumed's current tumor biobank of over 6000 patient-cases, collected with a mean cold ischemia time of less than eight minutes, serves as a resource for Indivumed's internal cancer research in biomarkers and primary cell drug screening as well as for the use of pharmaceutical and biopharma partners through tumor biobank access and IHC services.
SOURCE: Indivumed